Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07089940RecruitingEarly Phase 1
OMO-103 for advanced pancreatic cancer
This trial tests a new drug called OMO-103 in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It may be an option whether you have had treatment before or not, as long as it's been at least 2 weeks since your last therapy.
Portland, OregonAges 18 years+ - NCT06747832Enrolling by invitationEarly Phase 1
INK cells after chemoradiation for small cell lung cancer
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Weifang, Shandong Province, China.Ages 18–75 - NCT07383441RecruitingPhase 3
Adding Biotherapy or Placebo to Standard Kidney Cancer Treatment
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
Fayetteville, ArkansasAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06942234RecruitingPhase 1/Phase 2
Study of JSKN016 for advanced HER2-negative breast cancer
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
ShanghaiAges 18–75 - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07024173RecruitingPhase 3
Study of HRS-8080 for advanced breast cancer
This trial tests a new drug, HRS-8080, against other standard treatments chosen by your doctor for advanced or metastatic breast cancer. It's for women who have already tried 1-2 hormone therapies and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05651594RecruitingPhase 2
Propranolol with pembrolizumab and chemotherapy for esophageal cancer
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT05356741RecruitingPhase 1/Phase 2
Study drug VIR-5818 with and without pembrolizumab
This early trial tests whether VIR-5818 given through a vein is safe and whether it works better when combined with pembrolizumab. It’s for adults with HER2-positive cancers that are locally advanced or spread, and the study checks safety, side effects, and early signs of effect.
Melbourne, VictoriaAges 18 years+ - NCT06278545RecruitingPhase 2
Chemotherapy for unremovable small bowel cancer
This trial tests two standard chemotherapy combinations (FOLFIRINOX and FOLFOX) in people with small bowel adenocarcinoma that cannot be removed by surgery or has spread. It aims to see which works better for people who haven't had chemotherapy before.
DijonAges 18 years+ - NCT07391813RecruitingPhase 1/Phase 2
Testing SNB-101 for advanced small cell lung cancer
This study tests a new drug, SNB-101, for people with small cell lung cancer that has spread and has worsened after standard therapy. It aims to find out if SNB-101 can help control the cancer and what side effects it may cause.
KamenitzAges 18 years+ - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT06437509RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04539977RecruitingPhase 2
PD-L1 antibody plus chemotherapy for limited-stage small-cell lung cancer
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT05221372Recruiting
Sampling study for lung cancer patients on targeted pills
This trial collects blood samples from adults with advanced lung cancer that has a specific gene change and who are already taking targeted pill treatment (TKIs). The goal is to learn from these samples and how they relate to the cancer in patients on standard therapy.
RotterdamAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,558 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.